Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 11488956Search this ID in NIH RePORTER
- ScienceDex PI coverage
- FY2024 through FY2025Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
FY2025 award categories
- Biomedical Engineering
- Microbiology & Immunology
NIH Funding · FY2025
Linked Award Amount
$1.6M
Full award amounts, FY2025
Award Records
4
Records listing this PI
Award-Linked Rank
#9,343
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2025 award records by amount
NIH award records listing Sarah Elizabeth Rowe as a PI. Multi-PI records show the full award amount for context.
- 5R01AI167978-03R01A theranostic ultrasound approach to improve chronic wound treatment using phase-change contrast agents$536.1Kaward amount
- 1R21AI190273-01R21Elucidating the role of fimbriae in Klebsiella pneumoniae-mediated liver abscess formation$427.6Kaward amount
- 1R21AI187752-01A1R21Antibiotic treatment failure of Klebsiella pneumoniae liver abscesses$427.6Kaward amount
- 5R21AI180407-02R21Application of palmitoleic acid to potentiate antibiotic efficacy$194.4Kaward amount
Award organization
Organizations that administered FY2025 awards listing Sarah Elizabeth Rowe as a PI.
FY2025 award administered by University of North Carolina at Chapel Hill (NC).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardUniversity of North Carolina at Chapel Hill
- 2024$500K Cumulative Funding
- 2024R01 Grant Holder
- 2025$1M Cumulative Funding
- 2025$2M Cumulative Funding
- 2025Entered Top 50% NationallyRanked #9343
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Sarah Elizabeth Rowe.